- Home
- SLGL vs BIVI Comparison
SLGL vs BIVI Comparison
Compare SLGL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- BIVI
- Stock Information
- Founded
- SLGL 1997
- BIVI 2013
- Country
- SLGL Israel
- BIVI United States
- Employees
- SLGL N/A
- BIVI N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- BIVI Health Care
- Exchange
- SLGL Nasdaq
- BIVI Nasdaq
- Market Cap
- SLGL 19.3M
- BIVI 18.6M
- IPO Year
- SLGL 2018
- BIVI N/A
- Fundamental
- Price
- SLGL $8.14
- BIVI $7.19
- Analyst Decision
- SLGL Buy
- BIVI
- Analyst Count
- SLGL 1
- BIVI 0
- Target Price
- SLGL $40.00
- BIVI N/A
- AVG Volume (30 Days)
- SLGL 25.4K
- BIVI 41.7K
- Earning Date
- SLGL 08-15-2025
- BIVI 05-12-2025
- Dividend Yield
- SLGL N/A
- BIVI N/A
- EPS Growth
- SLGL N/A
- BIVI N/A
- EPS
- SLGL N/A
- BIVI N/A
- Revenue
- SLGL $12,103,000.00
- BIVI N/A
- Revenue This Year
- SLGL N/A
- BIVI N/A
- Revenue Next Year
- SLGL $31.17
- BIVI N/A
- P/E Ratio
- SLGL N/A
- BIVI N/A
- Revenue Growth
- SLGL 603.66
- BIVI N/A
- 52 Week Low
- SLGL $3.34
- BIVI $6.20
- 52 Week High
- SLGL $16.50
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- SLGL 63.80
- BIVI 31.41
- Support Level
- SLGL $6.96
- BIVI $6.78
- Resistance Level
- SLGL $7.48
- BIVI $10.30
- Average True Range (ATR)
- SLGL 0.28
- BIVI 0.86
- MACD
- SLGL 0.07
- BIVI -0.29
- Stochastic Oscillator
- SLGL 95.88
- BIVI 19.17
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.